Antiretrovirals in pregnancy: A note of caution

Journal of Infectious Diseases

Volumn 206, Issue 11, 2012, Pages 1639-1641

  Watts, D Heather ^a   Mofenson, Lynne M ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; EFAVIRENZ; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; RITONAVIR; ZIDOVUDINE;

BOTSWANA; BREAST FEEDING; CD4 LYMPHOCYTE COUNT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MATERNAL WELFARE; NEWBORN DEATH; NOTE; PRACTICE GUIDELINE; PREGNANCY; PREGNANCY OUTCOME; PREMATURE LABOR; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SINGLE DRUG DOSE; SMALL FOR DATE INFANT; STILLBIRTH; VERTICAL TRANSMISSION; WORLD HEALTH ORGANIZATION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREMATURE BIRTH; STILLBIRTH;

EID: 84869046661     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis581     Document Type: Note

References (26)

1. Townsend CL, Cortina-Borja M, Peckham CS, de Ruiter A, Lyall H, Tookey PA. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. AIDS 2008; 22:973-81.
2. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1- infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. 14 September 2011. http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf. Last accessed 03 July 2012.
3. World Health Organization. Programmatic update: use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants-executive summary. Geneva, Switzerland: World Health Organization, 2012. http://www.who.int/hiv/pub/mtct/programmatic-update2012/en/index. html. Last accessed 03 July 2012.
4. World Health Organization. Antiretroviral drugs for treating pregnant women and preventing HIV infections in infants: recommendations for a public health approach, 2010 version. Geneva, Switzerland: 2010. World Health Organization. http://www.who. int/hiv/pub/mtct/guidelines/en/. Last accessed 03 July 2012.
5. Kesho Bora Study Group; de Vincenzi I. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Lancet Infect Dis 2011; 11:171-80.
6. Chasela CS, Hudgens MG, Jamieson DJ, et al. Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. N Engl J Med 2010; 362:2271-81.
7. Thorne C, Patel D, Newell ML. Increased risk of adverse pregnancy outcomes in HIVinfected women treated with highly active antiretroviral therapy in Europe. AIDS 2004; 18:2337-9.
8. Cotter AM, Garcia AG, Duthely ML, Luke BO'Sullivan MJ. Is antiretroviral therapy during pregnancy associated with an increased risk of preterm delivery, low birth weight, or stillbirth? J Infect Dis 2006; 193:1195-201.
9. Kourtis AP, Schmid CH, Jamieson DJ, Lau J. Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: a meta-analysis. AIDS 2007; 21:607-15.
10. Townsend CL, Cortina-Borja M, Peckham CSTookey PA. Antiretroviral therapy and premature delivery in diagnosed HIVinfected women in the United Kingdom and Ireland. AIDS 2007; 21:1019-26.
11. Grosch-Woerner I, Puch K, Maier RF, et al. Increased rate of prematurity associated with antenatal antiretroviral therapy in a German/Austrian cohort of HIV-1-infected women. HIV Med 2008; 9:6-13.
12. Patel K, Shapiro DE, Brogly SB, et al. Prenatal protease inhibitor use and risk of preterm birth among HIV-infected women initiating antiretroviral drugs during pregnancy. J Infect Dis 2010; 201:1035-44.
13. Szyld EG, Warley EM, Freimanis L, et al. Maternal antiretroviral drugs during pregnancy and infant low birth weight and preterm birth. AIDS 2006; 20:2345-53.
14. Ekouevi DK, Coffie PA, Becquet R, et al. Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Côte d'Ivoire. AIDS 2008; 22:1815-20.
15. Ravizza M, Martinelli P, Bucceri A, et al. Treatment with protease inhibitors and coinfection with hepatitis C virus are independent predictors of preterm delivery in HIV-infected pregnant women. J Infect Dis 2007; 195:913-4.
16. Machado ES, Hofer CB, Costa TT, et al. Pregnancy outcome in women infected with HIV-1 receiving combination antiretroviral therapy before versus after conception. Sex Transm Infect 2009; 85:82-7.
17. Sibiude J, Warszawski J, Tubiana R, et al. ANRS CO1/CO11 Large increase in prematurity between 1990 and 2009 in HIVinfected women in the national ANRS French Perinatal Cohort: does ritonavir boost play a role? In: 18th Conference on Retroviruses and Opportunistic Infections; Feb 27-Mar 2, 2011, Boston, MA. Abstract 743.
18. Chen JY, Ribaudo HJ, Souda S, et al. Highly active antiretroviral therapy and adverse birth outcomes among HIV-infected women in Botswana. J Infect Dis 2012; 206:1695-705.
19. Schantz-Dunn J, Nour NM. Malaria and pregnancy: a global health perspective. Rev Obstet Gynecol 2009; 2:186-92.
20. Loto OM, Awowole I. Tuberculosis in pregnancy: a review. J Pregnancy 2012; 2012: 379271.
21. World Health Organization. Technical update on treatment optimization: use of efavirenz during pregnancy: a public health perspective. June 2012. Geneva, Switzerland: World Health Organization, 2012. http://www.who. int/hiv/pub/treatment2/efavirenz/en/index. html. Last accessed 03 July 2012.
22. Kuhn L, Aldrovandi GM, Sinkala M, Kankasa C, Mwiya M, Thea DM. Potential impact of new WHO criteria for antiretroviral treatment for prevention of mother-to-child transmission. AIDS 2010; 24:1374-7.
23. Van der Merwe K, Hoffman R, Black V, Chersich M, Coovadia A, Rees H. Birth outcomes in South African women receiving highly active antiretroviral therapy: a retrospective observational study. J Int AIDS Soc 2011; 14:42-52.
24. Lopez M, Figueras F, Hernandez S, et al. Association of HIV infection with spontaneous and iatrogenic preterm delivery: effect of HAART. AIDS 2012; 26:37-43.
25. Fiore S, Ferrazzi E, Newell ML, Trabattoni DClerici M. Protease inhibitor-associated increased risk of preterm delivery is an immunological complication of therapy. J Infect Dis 2007; 195:914-6.
26. Suy A, Martinez E, Coll O, Lonca M, et al. Increased risk of pre-eclampsia and fetal death in HIV-infected pregnant women receiving highly active antiretroviral therapy. AIDS 2006; 20:59-66.